Amends the Social Security Act to extend the exclusivity period for advanced drug products.

The Maintaining Investments in New Innovation Act amends the Social Security Act to extend the exclusivity period for advanced drug products from 7 years to 11 years. This change aims to protect access to genetically targeted technologies by providing a longer period of market exclusivity for qualifying single source drugs. The bill defines an advanced drug product as a drug that incorporates or utilizes a genetically targeted technology, potentially affecting gene function.

Amends the Social Security Act to extend the exclusivity period for advanced drug products.

The Maintaining Investments in New Innovation Act amends the Social Security Act to extend the exclusivity period for advanced drug products from 7 years to 11 years. This change aims to protect access to genetically targeted technologies by providing a longer period of market exclusivity for qualifying single source drugs. The bill defines an advanced drug product as a drug that incorporates or utilizes a genetically targeted technology, potentially affecting gene function.